Dermata Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Dermata Therapeutics, Inc. carries a market capitalization of 409.00, placing it among publicly traded companies globally. Its enterprise value stands at -4.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 409.00 |
| Enterprise Value | -4.37M |
Share Statistics
Dermata Therapeutics, Inc. currently has 4.02M shares outstanding.
| Shares Outstanding | 4.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.01 |
| P/TBV Ratio | 0.01 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Dermata Therapeutics, Inc. maintains a current ratio of 2.81, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.81 |
| Quick Ratio | 2.41 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -183.89 |
| Return on Assets (ROA) | -139.93 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Dermata Therapeutics, Inc.'s stock has declined approximately -97.28507% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.28507% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.60M, while operating income came in at -8.60M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.60M |
| Pretax Income | -8.37M |
| Net Income | -8.37M |
| EBITDA | -8.60M |
| EBIT | -8.60M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at 3.49M, with working capital of 3.32M providing operational flexibility.
| Cash & Cash Equivalents | 4.41M |
| Total Debt | N/A |
| Net Debt | -4.41M |
| Equity (Book Value) | 3.49M |
| Book Value Per Share | 0.87 |
| Working Capital | 3.32M |
Cash Flow
Dermata Therapeutics, Inc. produced -8.03M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.03M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.03M |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14,668.22 |
| FCF Yield | N/A |
Scores
Dermata Therapeutics, Inc. posts an Altman Z-Score of -25.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.11 |